JP2024527175A - レボドパと組み合わせるオピカポンを用いたパーキンソン病に関連する疼痛の治療 - Google Patents

レボドパと組み合わせるオピカポンを用いたパーキンソン病に関連する疼痛の治療 Download PDF

Info

Publication number
JP2024527175A
JP2024527175A JP2023543464A JP2023543464A JP2024527175A JP 2024527175 A JP2024527175 A JP 2024527175A JP 2023543464 A JP2023543464 A JP 2023543464A JP 2023543464 A JP2023543464 A JP 2023543464A JP 2024527175 A JP2024527175 A JP 2024527175A
Authority
JP
Japan
Prior art keywords
combination
score
patient
use according
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023543464A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022158992A5 (https=
JP2024527175A5 (https=
Inventor
パトリシオ、ソアレス、ダ、シルバ
ホセ、フランシスコ、ダ、コスタ、デ、ピノ、ロチャ
Original Assignee
ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ filed Critical ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ
Publication of JP2024527175A publication Critical patent/JP2024527175A/ja
Publication of JPWO2022158992A5 publication Critical patent/JPWO2022158992A5/ja
Publication of JP2024527175A5 publication Critical patent/JP2024527175A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023543464A 2021-01-20 2021-08-04 レボドパと組み合わせるオピカポンを用いたパーキンソン病に関連する疼痛の治療 Pending JP2024527175A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/PT2021/050001 WO2022158991A1 (en) 2021-01-20 2021-01-20 Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa
PTPCT/PT2021/050001 2021-01-20
PCT/PT2021/050026 WO2022158992A1 (en) 2021-01-20 2021-08-04 Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa

Publications (3)

Publication Number Publication Date
JP2024527175A true JP2024527175A (ja) 2024-07-22
JPWO2022158992A5 JPWO2022158992A5 (https=) 2024-07-29
JP2024527175A5 JP2024527175A5 (https=) 2024-07-29

Family

ID=74494985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543464A Pending JP2024527175A (ja) 2021-01-20 2021-08-04 レボドパと組み合わせるオピカポンを用いたパーキンソン病に関連する疼痛の治療

Country Status (5)

Country Link
US (1) US20240066015A1 (https=)
EP (1) EP4281071A1 (https=)
JP (1) JP2024527175A (https=)
CN (1) CN116963735A (https=)
WO (2) WO2022158991A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860603A1 (en) 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
EP4360627A1 (fr) * 2022-10-26 2024-05-01 Institut National de la Santé et de la Recherche Médicale (INSERM) Traitement de l'arthrose par des inhibiteurs de comt

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526663A (ja) * 2000-03-17 2003-09-09 オリオン コーポレーション Ｃｏｍｔ阻害剤の鎮痛剤としての用途
JP2014005275A (ja) * 2012-05-31 2014-01-16 Ono Pharmaceut Co Ltd 医薬用途
JP2017527623A (ja) * 2014-09-04 2017-09-21 ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法
JP2018500300A (ja) * 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
JP2018530612A (ja) * 2015-10-09 2018-10-18 テバ、ファーマスーティカルズ、インターナショナル、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｇｍｂｈ パーキンソン病の治療のための重水素化レボドパとカルビドパおよびオピカポンとの組合せ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024500754A (ja) * 2020-12-17 2024-01-10 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 早期特発性パーキンソン病のための治療レジメン

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526663A (ja) * 2000-03-17 2003-09-09 オリオン コーポレーション Ｃｏｍｔ阻害剤の鎮痛剤としての用途
JP2014005275A (ja) * 2012-05-31 2014-01-16 Ono Pharmaceut Co Ltd 医薬用途
JP2017527623A (ja) * 2014-09-04 2017-09-21 ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法
JP2018500300A (ja) * 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
JP2018530612A (ja) * 2015-10-09 2018-10-18 テバ、ファーマスーティカルズ、インターナショナル、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｇｍｂｈ パーキンソン病の治療のための重水素化レボドパとカルビドパおよびオピカポンとの組合せ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
TAI, YI-CHENG ET AL.: ""An overview of pain in Parkinson's disease"", CLINICAL PARKINSONISM & RELATED DISORDERS, vol. 2, JPN6025031520, 2020, pages 1 - 8, ISSN: 0005657409 *
大島秀規: "〈質問〉進行期パーキンソン病の腰・下肢痛に有効な治療は？", ペインクリニック, vol. 33(2), JPN6025031517, 2012, pages 285 - 286, ISSN: 0005657407 *
小野薬品工業株式会社, オピカポン（ONO-2370）、パーキンソン病における症状の日内変動の改善の効能・効果で国内製造販売承認申請, JPN6025031518, 27 February 2019 (2019-02-27), pages 1 - 2, ISSN: 0005657408 *

Also Published As

Publication number Publication date
WO2022158991A1 (en) 2022-07-28
CN116963735A (zh) 2023-10-27
WO2022158992A1 (en) 2022-07-28
US20240066015A1 (en) 2024-02-29
EP4281071A1 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
Sprenger et al. Management of motor and non-motor symptoms in Parkinson’s disease
Diener et al. Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology
Matharu et al. Management of trigeminal autonomic cephalgias and hemicrania continua
Gallagher et al. Impact of newer pharmacological treatments on quality of life in patients with Parkinson’s disease
Saarto et al. Antidepressants for neuropathic pain
AU2007235517B2 (en) Use of rasagiline for the treatment of Restless Legs Syndrome
Gupta Is chronic pain a variant of depressive illness? A critical review
Cohen et al. The pharmacologic treatment of muscle pain
JP2024050575A (ja) Ｌ－４－クロロキヌレニンの治療的使用
JP2024527175A (ja) レボドパと組み合わせるオピカポンを用いたパーキンソン病に関連する疼痛の治療
Alotaibi et al. Parkinson's disease: current treatment modalities and emerging therapies
JP2010530867A (ja) うつ病の治療
Oertel et al. Early (uncomplicated) Parkinson’s disease
CN115605195A (zh) 用于治疗大麻使用病症和缓解大麻素戒断的方法和组合物
Kataoka et al. Early-morning OFF in Parkinson’s disease: A systematic literature review and current therapeutics
van Laar et al. The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine
Williams-Gray et al. Parkinson's disease and related conditions
Picillo et al. Medical Management of Movement
JP2011121975A (ja) 線維筋痛症に伴う疼痛を改善するための線維筋痛症に伴う疼痛改善用医薬組成物
Aljohani The effect of dexamethasone sodium phosphate on surgical third molar extraction using pain, trismus, oedema, and quality of life as parameters: A comparative study
Rozental Tension-type headache, chronic tension-type headache, and other chronic headache types
Hanson et al. Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease
Singhal et al. Who is pushing patients to death trap by improper use of codeine? Time now to reorient physicians or ban the use of codeine!
JP2009539941A (ja) Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤
CA3076180C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20231006

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20231006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240717

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260203